BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Natco Pharma Ltd. would be the first company to launch Revlimid (lenalidomide) in March 2022 as Dr. Reddy’s Laboratories Ltd.'s settlement with Celgene over its patent clears the path for Natco Pharma.
Dr. Reddy’s would launch sometime after Natco Pharma (we assume six months) and would have market share restrictions lower than Natco Pharma in our view.
Till date, three companies (Natco Pharma, Dr. Reddy’s and Alvogen) have settled the litigation with innovator and would launch during this exclusivity period (FY23-FY26).
We expect the company to generate total revenue and profit after tax of 1.3 billion U.S. dollar and 900 million U.S dollar during the shared exclusivity period over FY23-FY26.
This would imply a net present of Rs 302 per share for Revlimid for Natco Pharma.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR